StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)

StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTHFree Report) in a research report released on Sunday morning. The firm issued a sell rating on the stock.

Separately, Roth Mkm boosted their price objective on shares of Bio-Path from $12.00 to $40.00 and gave the company a buy rating in a research report on Wednesday, March 27th.

Read Our Latest Research Report on BPTH

Bio-Path Price Performance

Shares of BPTH opened at $4.24 on Friday. Bio-Path has a one year low of $3.51 and a one year high of $44.80. The company has a market cap of $2.88 million, a P/E ratio of -0.10 and a beta of 0.36. The firm has a 50 day simple moving average of $6.76 and a two-hundred day simple moving average of $8.88.

Bio-Path (NASDAQ:BPTHGet Free Report) last announced its quarterly earnings data on Friday, March 8th. The company reported ($5.40) EPS for the quarter, meeting the consensus estimate of ($5.40). During the same quarter last year, the company earned ($10.60) EPS. On average, analysts expect that Bio-Path will post -20.8 earnings per share for the current fiscal year.

Institutional Trading of Bio-Path

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Virtu Financial LLC bought a new stake in shares of Bio-Path during the first quarter worth $38,000. Citadel Advisors LLC bought a new stake in shares of Bio-Path during the third quarter worth $35,000. Renaissance Technologies LLC bought a new stake in shares of Bio-Path during the second quarter worth $70,000. Vanguard Group Inc. grew its stake in shares of Bio-Path by 77.5% during the fourth quarter. Vanguard Group Inc. now owns 270,029 shares of the company’s stock worth $125,000 after buying an additional 117,914 shares during the last quarter. Finally, Walleye Capital LLC bought a new stake in shares of Bio-Path during the third quarter worth $77,000. Institutional investors own 5.74% of the company’s stock.

About Bio-Path

(Get Free Report)

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Recommended Stories

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.